Hydroxychloroquine Mitigates Dilated Cardiomyopathy Phenotype in Transgenic D94A Mice.

Hydroxychloroquine Mitigates Dilated Cardiomyopathy Phenotype in Transgenic D94A Mice.
复制标题

DOI:
10.3390/ijms232415589
复制
发表时间:
2022-12-09
影响因子:
5.6
通讯作者:
--
中科院分区:
生物学2区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

在这项研究中,我们的目的是调查是否短期和低剂量治疗羟氯喹(HCQ),抗疟疾药物,可以调节心脏功能的扩张型心肌病(DCM)的临床前模型表达D94 A突变的心肌肌球蛋白调节轻链(RLC)相比,健康的非转基因(NTg)的同窝仔。随着COVID-19大流行,对HCQ的兴趣增加,但HCQ心脏毒性副作用的风险引起了人们的担忧,特别是在患有基础心脏病的患者中,例如,心肌病通过超声心动图和肌肉收缩力学研究了在Tg-D94 A与NTg小鼠中施用超过一个月的HCQ治疗与安慰剂(H2O)的效果。整体纵向应变分析显示HCQ介导的DCM小鼠心脏性能的改善。在分子水平上,HCQ促进了DCM-D94 A心肌肌球蛋白超松弛(SRX)状态向无序松弛(DRX)状态的转变。这一结果表明更多的肌球蛋白跨桥退出低收缩SRX-OFF状态并呈现DRX-ON状态,从而潜在地增强DCM小鼠中的肌球蛋白运动功能。在肌球蛋白分子、肌纤维和整个心脏水平上对HCQ的药理学用途的这种自下而上的研究为HCQ治疗减轻DCM-D94 A小鼠中的一些异常表型并对健康NTg心脏不造成伤害的机制提供了新的见解。
In this study, we aimed to investigate whether short-term and low-dose treatment with hydroxychloroquine (HCQ), an antimalarial drug, can modulate heart function in a preclinical model of dilated cardiomyopathy (DCM) expressing the D94A mutation in cardiac myosin regulatory light chain (RLC) compared with healthy non-transgenic (NTg) littermates. Increased interest in HCQ came with the COVID-19 pandemic, but the risk of cardiotoxic side effects of HCQ raised concerns, especially in patients with an underlying heart condition, e.g., cardiomyopathy. Effects of HCQ treatment vs. placebo (H2O), administered in Tg-D94A vs. NTg mice over one month, were studied by echocardiography and muscle contractile mechanics. Global longitudinal strain analysis showed the HCQ-mediated improvement in heart performance in DCM mice. At the molecular level, HCQ promoted the switch from myosin’s super-relaxed (SRX) to disordered relaxed (DRX) state in DCM-D94A hearts. This result indicated more myosin cross-bridges exiting a hypocontractile SRX-OFF state and assuming the DRX-ON state, thus potentially enhancing myosin motor function in DCM mice. This bottom-up investigation of the pharmacological use of HCQ at the level of myosin molecules, muscle fibers, and whole hearts provides novel insights into mechanisms by which HCQ therapy mitigates some abnormal phenotypes in DCM-D94A mice and causes no harm in healthy NTg hearts.
DOI: 10.1038/nature02145
发表时间: 2003-11-27
期刊: Nature
影响因子: 64.8
作者:
Li W;Moore MJ;Vasilieva N;Sui J;Wong SK;Berne MA;Somasundaran M;Sullivan JL;Luzuriaga K;Greenough TC;Choe H;Farzan M
通讯作者: Farzan M
DOI: 10.1016/j.hfc.2017.12.004
发表时间: 2018-04
影响因子: 3.4
作者:
Garfinkel AC;Seidman JG;Seidman CE
通讯作者: Seidman CE
DOI: 10.1161/circresaha.116.309396
发表时间: 2017-09-15
影响因子: 20.1
作者:
McNally EM;Mestroni L
通讯作者: Mestroni L
DOI: 10.1007/s003800200043
发表时间: 2002-12-01
期刊: HEART AND VESSELS
影响因子: 1.5
作者:
Hara, Y;Hamada, M;Shigematsu, Y
通讯作者: Shigematsu, Y
DOI: 10.4049/jimmunol.1400571
发表时间: 2014-10-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
Le NT;Takei Y;Izawa-Ishizawa Y;Heo KS;Lee H;Smrcka AV;Miller BL;Ko KA;Ture S;Morrell C;Fujiwara K;Akaike M;Abe J
通讯作者: Abe J